Cat. No.: HY-A0144A

Etilefrine hydrochloride

Customer Review

Based on 1 Customer Validation

Etilefrine hydrochloride is a sympathetic nerve agonist and AMPK activator that selectively targets α1/β1 adrenergic receptors. Etilefrine hydrochloride stimulates α1 adrenergic receptors, leading to contraction of vascular smooth muscle and increased peripheral resistance. Etilefrine hydrochloride also stimulates β1 receptors to enhance myocardial contractility and increase heart rate, thereby increasing blood pressure and improving cardiac output. Etilefrine hydrochloride also bidirectionally regulates the AMPK/Akt pathway and modulates the phosphorylation levels. Etilefrine hydrochloride can be used in cardiovascular research, such as postural hypotension, chylothorax, and improving low cardiac output.

For research use only. We do not sell to patients.

Purity: 99.90%
CAS No.: 943-17-9
Formula: C₁₀H₁₆ClNO₂
Molecular Weight:217.70

Storage:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Etilefrine hydrochloride Chemical Structure

CAS No.: 943-17-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

α1-adrenergic receptor

Beta-1 adrenergic receptor

All Adrenergic Receptor Isoforms :

All Akt Isoforms :

All AMPK Isoforms :

In Vitro

Etilefrine hydrochloride (10 μM; 1-2 h) significantly activates AMPKα (Thr172) phosphorylation and inhibits Akt (Ser473) phosphorylation in PC-3 and 293T cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

PC-3 (human prostate cancer), 293T (human embryonic kidney)
Concentration:

5, 10, 50 μM
Incubation Time:

1 h or 2 h
Result:

Increased phosphorylated AMPKα (Thr172) by 1.5-2.0 fold and decreased phosphorylated Akt (Ser473) by 0.2-0.4 fold compared to controls, indicating AMPK activation and Akt inhibition in both cell lines.

In Vivo

Etilefrine (0.1 mg/kg; intravenous injection; single dose) hydrochloride causes an increase in blood pressure and heart rate in anesthetized mongrel dog models, which may be related to the constriction of resistance vessels and the increase in cardiac contractility and heart rate^[2].
Etilefrine (50 μg/kg, 200 μg/kg; intravenous injection; single dose) hydrochloride can increase cardiac output, right heart filling pressure and blood pressure at rest and reduce total peripheral resistance in New Zealand white rabbit experimental models. Total peripheral resistance increased at a dose of 200 μg/kg^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Anesthetized mongrel dogs (8.5-14 kg), postural hypotension model induced by hexamethonium and 30° tilt^[2]
Dosage:

0.1 mg/kg
Administration:

Intravenous injection, single dose, acute experiment
Result:

Significantly increased basal blood pressure (BP) and heart rate (HR). During tilt, it did not attenuate the decrease in systolic, diastolic, or mean BP, but tended to increase cardiac output (CO) without significant attenuation of tilt-induced CO reduction.

Animal Model:

New Zealand white rabbits (male, 3.0-4.1 kg), resting cardiovascular function model^[3]
Dosage:

50 μg/kg, 200 μg/kg
Administration:

Intravenous injection, single dose, acute experiment
Result:

At 50 μg/kg, increased right heart filling pressure (RHFP), cardiac output (CO), and blood pressure (BP), reduced total peripheral resistance (TPR), and caused bradycardia.
At 200 μg/kg, it increased RHFP, BP, and TPR, while CO showed a minor decrease, indicating mixed α and β adrenoceptor-mediated effects.

Chemical Information

CAS No. 943-17-9
Appearance Solid
Molecular Weight 217.70
Formula C₁₀H₁₆ClNO₂
Color White to off-white
SMILES

OC(CNCC)C1=CC=CC(O)=C1.[H]Cl
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (459.36 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.5936 mL

22.9678 mL

45.9356 mL

5 mM

0.9187 mL

4.5936 mL

9.1871 mL

10 mM

0.4594 mL

2.2968 mL

4.5936 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (11.48 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (11.48 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (11.48 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Korean - KR (479 KB)
- Portuguese - PT (479 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Chi Xu, et al. Accurate Drug Repositioning through Non-tissue-Specific Core Signatures from Cancer Transcriptomes. Cell Rep. 2018 Oct 9;25(2):523-535.e5. [Content Brief]

[2]. R Yamazaki, et al. Effects of dihydroergotamine and Etilefrine on experimentally-induced postural hypotension in dogs. J Pharmacobiodyn. 1990 Sep;13(9):519-24. [Content Brief]

[3]. Adigun SA, et al. A comparison of the effects of salbutamol, etilefrine and dextran during hypotension and low cardiac output states in rabbit. Clin Exp Pharmacol Physiol. 1984 Nov-Dec;11(6):627-43. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.5936 mL	22.9678 mL	45.9356 mL	114.8390 mL
	5 mM	0.9187 mL	4.5936 mL	9.1871 mL	22.9678 mL
	10 mM	0.4594 mL	2.2968 mL	4.5936 mL	11.4839 mL
	15 mM	0.3062 mL	1.5312 mL	3.0624 mL	7.6559 mL
	20 mM	0.2297 mL	1.1484 mL	2.2968 mL	5.7420 mL
	25 mM	0.1837 mL	0.9187 mL	1.8374 mL	4.5936 mL
	30 mM	0.1531 mL	0.7656 mL	1.5312 mL	3.8280 mL
	40 mM	0.1148 mL	0.5742 mL	1.1484 mL	2.8710 mL
	50 mM	0.0919 mL	0.4594 mL	0.9187 mL	2.2968 mL
	60 mM	0.0766 mL	0.3828 mL	0.7656 mL	1.9140 mL
	80 mM	0.0574 mL	0.2871 mL	0.5742 mL	1.4355 mL
	100 mM	0.0459 mL	0.2297 mL	0.4594 mL	1.1484 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Etilefrine hydrochloride

Epigenetics Compound Library

GPCR/G Protein Compound Library

Kinase Inhibitor Library

Neuronal Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Neurotransmitter Receptor Compound Library

Glutamine Metabolism Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Serine/Threonine Kinase Inhibitor Library

Anti-Drug-Resistant Compound Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Lactylation Compound Library

All Adrenergic Receptor Isoforms

All Akt Isoforms

All AMPK Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Etilefrine hydrochloride Related Classifications

HY-A0144A Related Classifications